Publications

  • Selective Recruitment of Antibodies to Cancer Cells and Immune Cell‐mediated Killing via In Situ Click Chemistry. Ankrom, E. T.; Dalesandro, B.; Pires, M. M.; Thévenin, D. ChemMedChem, 2024, 2024, e202400356. doi:10.1002/cmdc.202400356. Link

  • Targeted Acidosis Mediated Delivery of Antigenic MHC-Binding Peptides. Kelly, J. J.; Ankrom, E. T.; Newkirk, S. E.; Thévenin, D.; Pires, M. M. Front. Immunol., 2024, 15. doi:10.3389/fimmu.2024.1337973. Link

  • Promoting the Activity of a Receptor Tyrosine Phosphatase with a Novel pH‐responsive Transmembrane Agonist Inhibits Cancer‐Associated Phenotypes. Rizzo, S.; Sikorski, E.; Park, S.; Im, W.; Vasquez‐Montes, V.; Ladokhin, A. S.; Thévenin, D. Protein Science, 2023, 32(9):e4742. doi:10.1002/pro.4742. Link

  • Disrupting PTPRJ transmembrane-mediated oligomerization counteracts oncogenic receptor tyrosine kinase FLT3 ITD. Schwarz, M.; Rizzo, S.; Espinoza Paz, W.; Kresinsky, A.; Thévenin, D.; Müller, J.P. Front. Oncol., 2022, 12:1017947. doi:10.3389/fonc.2022.1017947. Link

  • Ca2+ and Mg2+ Influence the Thermodynamics of Peptide-Membrane Interactions. Vasquez-Montes, V.; Goldberg, A.F. X.; Thévenin, D.; Ladokhin, A.S. J. Mol. Bio, 2022, 434(21):167826. doi:110.1016/j.jmb.2022.167826. Link

  • Ca2+ -dependent interactions between lipids and the tumor-targeting peptide pHLIP. Vasquez-Montes V*, Tyagi V*, Sikorski E*, Kyrychenko A, Freites JA, Thévenin D, Tobias DJ, Ladokhin AS. Protein Science, 2022, 31(9):e4385. doi:10.1002/pro.4385. (*equal contribution) Link

  • Selective Display of a Chemoattractant Agonist on Cancer Cells Activates the Formyl Peptide Receptor 1 on Immune Cells. Sikorski E, Wehr J, Ferraro NJ, Rizzo S, Pires MM, Thévenin, D. ChemBioChem, 2022, 23(8):e202100521. doi:10.1002/cbic.202100521. PubMed

  • pH-Dependent Grafting of Cancer Cells with Antigenic Epitopes Promotes Selective Antibody-Mediated Cytotoxicity. Wehr J, Sikorski EL, Bloch E, Feigman MS, Ferraro NJ, Baybutt TR, Snook AE, Pires MM, Thévenin D. J Med Chem., 2020, 63 (7), 3713–3722. doi: 10.1021/acs.jmedchem.0c00016. PubMed

  • Divalent Cations and Lipid Composition Modulate Membrane Insertion and Cancer-Targeting Action of pHLIP. Vasquez-Montes V, Gerhart J, Damien Thévenin, Ladokhin AS.  J. Mol. Bio, 2019; doi: 10.1016/j.jmb.2019.10.016. PubMed

  • Disrupting the transmembrane domain-mediated oligomerization of protein tyrosine phosphatase receptor J inhibits EGFR-driven cancer cell phenotypes. Elizabeth Bloch*, Eden L. Sikorski*, David Pontoriero, Bryan Berger, Matthew J. Lazzara, Damien Thévenin. J. Biol. Chem, 2019; doi: 10.1074/jbc.RA119.010229. (*equal contribution)  PubMed

  • Inhibiting Epidermal Growth Factor Receptor Dimerization and Signaling Through Targeted Delivery of a Juxtamembrane Domain Peptide Mimic. Gerhart J, Thévenin AF , Bloch E, King KE, Thévenin D. ACS Chem Biol., 2018, 21;13(9):2623–32. PubMed

  • Comparison of lipid-dependent bilayer insertion of pHLIP and its P20G variant. Vasquez-Montes V, Gerhart J, King KE, Thévenin D, Ladokhin AS. BBA Biomembranes, 2017, 1860(2):534–43. PubMed

  • Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells and Mouse Models. Burns KE, Hensley HH, Robinson MK, Thévenin D. Molecular Pharmaceutics, 2017, Feb 6;14(2):415-422. PubMed

  • pH-Selective Cytotoxicity of pHLIP-Antimicrobial Peptide Conjugates. Burns KE, McCleerey TP (UG), Thévenin D. Scientific Reports, 2016, 2016;6:28465. PubMed

  • Down-regulation of PAR1 activity with a pHLIP-based allosteric antagonist induces cancer cell death. Burns KE, Thévenin D. Biochemical Journal, 2015, 472(3), 287–95. PubMed

  • Taming Amphotericin B. Janout V, Schell WA, Thévenin D, Yu Y, Perfect JR, Regen SL. Bioconjug Chem, 2015, 26(10), 2021–4. PubMed

  • Inhibition of Cancer Cell Proliferation and Breast Tumor Targeting of pHLIP-Monomethyl Auristatin E Conjugates. Burns K, Robinson M, Thévenin D. Molecular Pharmaceutics, 2015, 12(4), 1250–8. PubMed

  • Peptide targeting and imaging of damaged lung tissue in influenza-infected mice. Li N, Yin L, Thévenin D, Yamada Y, Limmon G, Chen J, et al. Future Microbiol, 2013, 8, 257–69. PubMed

  • Identifying and Measuring Transmembrane Helix-Helix Interactions by FRET. Thévenin D*, Lazarova T. Methods Mol Biol, 2012, 914, 87–106. PubMed

  • Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation. Matthews EE*, Thévenin D*, Rogers JM, Gotow L, Lira PD, Reiter LA, William H Brissette, Donald M Engelman. FASEB Journal, 2011, 25(7), 2234–44. (*equal contribution). PubMed

  • pHLIP-mediated translocation of membrane-impermeable molecules into cells. Thévenin D, An M, Engelman DM. Chemistry & Biology, 2009, 16(7), 754–62. PubMed

  • Stable interactions between the transmembrane domains of the adenosine A2A receptor. Thévenin D*, Lazarova T. (2008). Protein Science, 2008, 17(7), 1188–99. PubMed

  • Identifying interactions between transmembrane helices from the adenosine A2A receptor. Thévenin D, Roberts MF, Lazarova T, Robinson CR. Biochemistry, 2005, 44(49), 16239–45. PubMed

  • Oligomerization of the fifth transmembrane domain from the adenosine A2A receptor. Thévenin D, Lazarova T, Roberts MF, Robinson CR. Protein Science, 2005, 14(8), 2177–86. PubMed


  •